SLF1081851|cas:2763730-97-6|西域试剂

SLF1081851,98.11%

产品编号：Bellancom-149004| CAS NO：2763730-97-6| 分子式：C₂₁H₃₃N₃O| 分子量：343.51

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-149004	￥1500.00	杭州北京（现货）
Bellancom-149004	￥2400.00	杭州北京（现货）
Bellancom-149004	￥5100.00	杭州北京（现货）
Bellancom-149004	￥8500.00	杭州北京（现货）
Bellancom-149004	￥13500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

SLF1081851

产品介绍

SLF1081851 是一种 Spns2 抑制剂，抑制 S1P 释放 (IC₅₀=1.93 μM)。SLF1081851在发育和免疫系统中起关键作用。

生物活性

SLF1081851 is a Spns2 inhibitor, inhibits S1P release (IC₅₀=1.93 μM). SLF1081851 plays a key role in development and immune system.

体外研究

Sphingosine 1-phosphate (S1P) is a pleiotropic signaling molecule, and Spns2 exerts the functions to maintain lymph S1P.
SLF1081851 (compound 16d) (0-5 μM; 18-20 h) inhibits S1P release with an IC₅₀ value of 1.93 μM in Hela cells.
SLF1081851 (0-30 μM; 20 min) inhibits mSphK1 (recombinant mouse SphK) (10 μM) and mSphK2 (5 μM) in a dose-dependent manner and suggests at least 15-fold selectivity (SphK1 IC₅₀≥30 μM; SphK2 IC₅₀≈30 μM).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

SLF1081851 (20 mg/kg; i.p., 4 h postdose) significantly inhibits circulating lymphocytes and plasma S1P, and recapitulates the genetic phenotype of Spns2 null mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection; blood was drawn 4 h postdose
Result:	Significantly decreased circulating lymphocyte count and plasma S1P concentration.

Animal Model:	SpragueDawley mice (4-week-old)
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; single dose; measured at 0, 0.5, 1, 2, 4, 6, and 24 h postdose
Result:	Reached a maximum concentration of 5 μM in blood at 2 h with drug levels sustained at ≥ 2 μM for at least 24 h, proved a half-life of over 8 h in rats. The appearance of SPNS2-IN-1 in circulation correlated with a maximal decrease in lymphocyte count at 4 h (25% lower compared to time =0).

体内研究

SLF1081851 (20 mg/kg; i.p., 4 h postdose) significantly inhibits circulating lymphocytes and plasma S1P, and recapitulates the genetic phenotype of Spns2 null mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice
Dosage:	20 mg/kg
Administration:	Intraperitoneal injection; blood was drawn 4 h postdose
Result:	Significantly decreased circulating lymphocyte count and plasma S1P concentration.

Animal Model:	SpragueDawley mice (4-week-old)
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; single dose; measured at 0, 0.5, 1, 2, 4, 6, and 24 h postdose
Result:	Reached a maximum concentration of 5 μM in blood at 2 h with drug levels sustained at ≥ 2 μM for at least 24 h, proved a half-life of over 8 h in rats. The appearance of SPNS2-IN-1 in circulation correlated with a maximal decrease in lymphocyte count at 4 h (25% lower compared to time =0).

性状

Solid

溶解性数据

In Vitro:

Ethanol : 10 mg/mL (29.11 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.9111 mL	14.5556 mL	29.1112 mL
5 mM	0.5822 mL	2.9111 mL	5.8222 mL
10 mM	0.2911 mL	1.4556 mL	2.9111 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

参考文献